Lecheng Pilot Zone attracts consumers with innovation

As of the end of 2022, the Boao Lecheng International Medical Tourism Pilot Zone had imported 290 licensed drugs and medical devices that were first introduced to China. The number of patients using licensed drugs and medical services has reached nearly 18,000, a year-on-year increase of 79 percent. In 2022, the value of goods stored in the Lecheng public bonded warehouse was 488 million yuan ($70.55 billion), an increase of 80 percent year-on-year.

As a pilot zone of China's medical and pharmaceutical reform and innovative development, how can Lecheng Pilot Zone attract the attention of consumers and continuously tap into the attraction of innovation?

First, Lecheng Pilot Zone is gradually transforming from an area led by policies to an area orientated toward the innovative development of its health industry.

Second, since last year, Lecheng Pilot Zone has cooperated with many domestic and overseas pharmaceutical and medical equipment enterprises, as well as with Haikou National Hi-tech Industrial Development Zone on the improvement of the ecology of the biomedical industry, and has safeguarded pharmaceutical enterprises' research and development and production. The Trilaciclib researched and developed by Simcere Pharmaceutical Group Limited in Lecheng Pilot Zone has completed its registration and listing in China. The medicine will be produced in Haikou National Hi-tech Industrial Development Zone, and Lecheng Pilot Zone will share in the economic benefits.

In the past year, Lecheng Pilot Zone maintained a good momentum and registered stellar performance in development and innovation.